Search Results for: Università di Padova: scoperta molecola a base di rame che colpisce i tumori solidi

In Reply We thank Dr Cohen for his comments. We agree that the “adequacy” of dialysis measured by urea removal is an important concept, relevant to both nephrologists and general medicine clinicians. Due to space limitations, we were unable to include this topic in our Review. Of note, the appropriateness of the term adequacy has been questioned in recent years. Measures of small solute (ie, urea) removal do not capture potassium or acid-base homeostasis, fluid or middle molecule (ie, molecules weighing 500-15 000 Da, such as beta-2 microglobulin and endotoxin fragments) removal, or patient-prioritized outcomes, such as symptoms and quality of life. Experts now recognize the insufficiency of urea clearance as an adequacy marker and recommend characterizing optimal dialysis by patient-reported and clinical measures. Guidelines support individualizing dialysis care, endorsing a goal-directed approach that incorporates patient priorities and preferences while maintaining quality and safety. Measures of urea removal remain important parameters to consider, but such laboratory values should not be used in isolation when prescribing the length of hemodialysis treatments and the number of peritoneal dialysis exchanges.

Protegge cuore, nervi, cervello e migliora la qualità di vita

Introduction
Recurrent urinary tract infections (rUTIs) are typically treated using antibiotics. Given the growing issue of antimicrobial resistance, non-antibiotic management options for rUTIs have faced a recent resurgence in popularity. Methenamine hippurate is a urinary antiseptic used as a non-antibiotic prophylactic measure in those with rUTIs. The results of a recent randomised controlled trial showed methenamine hippurate to perform on par with antibiotic prophylaxis in adult women with rUTIs. However, little is known about the efficacy of methenamine hippurate in vulnerable patient populations, such as children, the elderly, patients with indwelling catheters and those with renal tract abnormalities. Moreover, an up-to-date, comprehensive evaluation of the entirety of the literature surrounding methenamine hippurate has yet to be carried out. As such, key trends within the literature, such as common side effects and specific avenues for future research, are difficult to determine. Therefore, we developed the methodology for a scoping review to map the entirety of the existing evidence base for methenamine hippurate.

Methods and analysis
The protocol for this scoping review was developed in accordance with the framework set out by Arksey and O’Malley. We will search MEDLINE, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ProQuest Dissertation and Theses from inception until August 2024, with no language restrictions applied. Studies including patients of any age and sex receiving methenamine hippurate treatment, either as a primary or adjunct treatment for rUTIs, will be eligible for inclusion. Interventional studies, such as randomised controlled trials and their protocols, non-randomised clinical trials, cohort studies, case-control studies and observational studies of any design, will be included. Grey literature, systematic reviews and qualitative studies will also be included. Two independent reviewers blinded to each other’s decisions will assess the eligibility of articles at each stage using the Covidence review platform. After the relevant data from each study has been extracted, we will report the results of our scoping review using descriptive summary statistics and a narrative thematic analysis.

Ethics and dissemination
Due to the nature of the present study, ethical approval was not required for this scoping review. The final manuscript of this scoping review will be published in an international, peer-reviewed journal and the findings of the review presented in relevant national and international conferences.

The US is entering a time of great chaos and uncertainty in medicine, health care, and public health. Amid this background, the need for peer-reviewed scientific evidence has never been greater. JAMA Internal Medicine renews its unwavering commitment to providing this evidence base for medicine and health care and reaffirms its fundamental mission of advancing the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive articles.

Prima e dopo la chirurgia. Primo studio positivo in oltre vent’anni

La cofondatrice dell’Università Cattolica beatificata 3 anni fa

Introduction
Falls can lead to serious health-related consequences in the older population. If an emergency occurs within the home environment of an older person living alone, the initiation of emergency care can be delayed, leading to even worse outcomes for this population. Smart home emergency call systems (HECSs) can detect falls and automatically trigger an emergency alarm, potentially reducing time to emergency care and improving outcomes. The INES (Intelligentes NotfallErkennungsSystem—smart emergency detection system) study is a prospective randomised controlled trial conducted in three German federal states that aims to investigate the effectiveness and cost-effectiveness of a smart HECS.

Methods and analysis
Following a telephone interview, individuals aged 70 years or older, living alone, at risk of falling and willing to participate are included in the study. Participants are assigned to one of two groups depending on their previous use of a HECS. Based on the sample size calculation, the study aims to recruit n=498 participants already using a standard HECS (group A) and n=1378 participants who have not used a HECS before (group B). Within both groups, participants are randomised into the intervention arm (IA) and control arm (CA). The IA receives a smart HECS during the 21-month follow-up period. In addition to a standard HECS with a base station and a wearable radio transmitter, the smart HECS includes sensors that can detect falls and automatically trigger an alarm. The primary outcome assessed will be the days spent in the hospital after an emergency admission. Secondary outcomes include the utilisation of healthcare services and their total costs, progression of care dependency, fear of falling (Falls Efficacy Scale—International), health-related quality of life (EQ-5D-5L) and well-being (ICEpop CAPability measure for Older people).

Ethics and dissemination
The design and conceptualisation of the INES study were approved by the ethics committee of the Hamburg Medical Association on 26 June 2023 (2023-101032-BO-ff). Results of the INES study will be published in peer-reviewed articles.

Trial registration number
Deutsches Register Klinischer Studien, German Clinical Trials Register DRKS00031408. Registered on 28 June 2023.

Nuovo centro di Teragnostica. Schillaci, ‘branca tra le più promettenti, per terapie sempre più personalizzate e diagnosi sempre più precoci’

A Padova 700 esperti a confronto nel congresso Emsos

A Padova riuniti i maggiori esperti nel 37/o congresso Emsos

Erogato un contributo per ricerca contro i tumori del sangie

Erogato un contributo per ricerca contro i tumori del sangie